A study to investigate the safety, tolerability, and pharmacokinetics of AZD7503 in Japanese healthy participants.

Exclusion Criteria

• -History of any clinically significant disease or disorder in the investigator's opinion.
• - History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• - Any clinically important illness, medical/surgical procedure or trauma.
• - Any abnormal laboratory values, clinical chemistry, hematology or urinalysis results, vital signs, Electrocardiography.
• -Any clinically significant cardiovascular event.
• -Participants with known autoimmune disease or on-treatment with immune-modulatory drugs.
• -Any positive result at the Screening Visit for serum Hepatitis B surface antigen, hepatitis C antibody and Human Immunodeficiency virus.
• - Confirmed COVID-19 infection during screening as per local guidelines.
• - History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity.
• -Use of any prescribed or nonprescribed medication.
• -History of major bleed or high-risk of bleeding diathesis.
• -Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study intervention.
• -Participants who have previously received AZD7503 or any investigational drug targeting HSD17B13.
• -Vulnerable participants.